Physician profile
Clara Loter
NPI 1245970086
$3,112.17
in general payments reported to CMS, 2019-2025
19 companies · $865 in 2025
The $865 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $572 · 2024: $1,674 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,112.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $827.02 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $511.63 | 2023-2025 | |
| Amgen INC. | $320.08 | 2023-2025 | Tezspire |
| Glaxosmithkline, LLC. | $314.48 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $196.85 | 2023-2025 | Dupixent |
| Csl Behring | $164.57 | 2023-2025 | Haegarda |
| Novartis Pharmaceuticals Corporation | $136.58 | 2023-2025 | |
| Pfizer INC. | $87.43 | 2023-2024 | |
| Grifols USA, LLC | $83.93 | 2023-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $81.25 | 2024-2025 | Eohilia, Hyqvia |
| Genentech USA, INC. | $77.45 | 2024 | Xolair, Xofluza |
| Ars Pharmaceuticals Operations, INC. | $70.10 | 2025 | Neffy |
| Exact Sciences Corporation | $53.57 | 2023 | Cologuard Collection Kit |
| Octapharma USA, INC. | $50.81 | 2023-2024 | Cutaquig |
| Cycle Pharmaceuticals INC | $41.53 | 2024-2025 | Sajazir |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $38.77 | 2023-2025 | Orladeyo |
| Kaleo, INC. | $24.84 | 2023 | Auvi-Q |
| Phadia US INC. | $16.39 | 2024 | Immunocap |
| Hikma Pharmaceuticals USA | $14.89 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Loter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.